Difference between revisions of "P63"

From Libre Pathology
Jump to navigation Jump to search
m (rare P63 +ve prostate cancers)
 
(10 intermediate revisions by one other user not shown)
Line 1: Line 1:
[[Image:High_grade_squamous_intraepithelial_lesion_-_2_-_p63_--_intermed_mag.jpg |thumb|right|350px| Nuclear staining is characteristic of p63.]]
{{ Infobox immunostain
| Name      = {{PAGENAME}}
| Image     = High_grade_squamous_intraepithelial_lesion_-_2_-_p63_--_intermed_mag.jpg
| Width      =
| Caption    = p63 staining in squamous epithelium with dysplasia.
| Abbrev    =
| Synonyms  =
| Similar    = [[p40]] (more [[specificity|specific]] for squamous cell carcinoma)
| Clones    =     
| Use        = breast pathology (invasion vs. in situ), prostate pathology (HGPIN vs. cancer), lung (adenocarcinoma vs. squamous)
| Subspecial = 
| Pattern    = nuclear staining
| Positive  = [[squamous cell carcinoma]], [[urothelial carcinoma]]
| Negative  = [[prostate carcinoma]], most [[lung adenocarcinoma]], breast carcinoma
| Other      =
}}
'''p63''' is a commonly used [[immunostain]].  p63, like most other "p" stains, is a nuclear stain.
'''p63''' is a commonly used [[immunostain]].  p63, like most other "p" stains, is a nuclear stain.


==Pattern==
==Pattern==
*Nuclear staining.
*Nuclear staining.
*Stains basal cells in a normal squamous epithelium.
**Superficial cells are typically negative.
**In dysplasia, the staining is seen more superficially,<ref name=pmid19700941>{{Cite journal  | last1 = Houghton | first1 = O. | last2 = McCluggage | first2 = WG. | title = The expression and diagnostic utility of p63 in the female genital tract. | journal = Adv Anat Pathol | volume = 16 | issue = 5 | pages = 316-21 | month = Sep | year = 2009 | doi = 10.1097/PAP.0b013e3181b507c6 | PMID = 19700941 }}</ref> as one might expect as most squamous carcinomas are positive for p63.


Note:
Note:
*Cytoplasmic staining suggestive of muscle differentiation - seen in [[rhabdomyosarcoma]].<ref name=pmid21623385>{{Cite journal  | last1 = Martin | first1 = SE. | last2 = Temm | first2 = CJ. | last3 = Goheen | first3 = MP. | last4 = Ulbright | first4 = TM. | last5 = Hattab | first5 = EM. | title = Cytoplasmic p63 immunohistochemistry is a useful marker for muscle differentiation: an immunohistochemical and immunoelectron microscopic study. | journal = Mod Pathol | volume = 24 | issue = 10 | pages = 1320-6 | month = Oct | year = 2011 | doi = 10.1038/modpathol.2011.89 | PMID = 21623385 }}</ref>
*Cytoplasmic staining suggestive of muscle differentiation - seen in [[rhabdomyosarcoma]].<ref name=pmid21623385>{{Cite journal  | last1 = Martin | first1 = SE. | last2 = Temm | first2 = CJ. | last3 = Goheen | first3 = MP. | last4 = Ulbright | first4 = TM. | last5 = Hattab | first5 = EM. | title = Cytoplasmic p63 immunohistochemistry is a useful marker for muscle differentiation: an immunohistochemical and immunoelectron microscopic study. | journal = Mod Pathol | volume = 24 | issue = 10 | pages = 1320-6 | month = Oct | year = 2011 | doi = 10.1038/modpathol.2011.89 | PMID = 21623385 }}</ref>


==Classic use==
==Staining==
Subtype marker:
===Positive - common use===
*Marker of [[squamous cell carcinoma]].
*Marker of [[squamous cell carcinoma]].
*[[Urothelial carcinoma]].<ref name=pmid15976812>{{Cite journal  | last1 = Lewis | first1 = JS. | last2 = Ritter | first2 = JH. | last3 = El-Mofty | first3 = S. | title = Alternative epithelial markers in sarcomatoid carcinomas of the head and neck, lung, and bladder-p63, MOC-31, and TTF-1. | journal = Mod Pathol | volume = 18 | issue = 11 | pages = 1471-81 | month = Nov | year = 2005 | doi = 10.1038/modpathol.3800451 | PMID = 15976812 | URL = http://www.nature.com/modpathol/journal/v18/n11/full/3800451a.html}}</ref>
*[[Urothelial carcinoma]].<ref name=pmid15976812>{{Cite journal  | last1 = Lewis | first1 = JS. | last2 = Ritter | first2 = JH. | last3 = El-Mofty | first3 = S. | title = Alternative epithelial markers in sarcomatoid carcinomas of the head and neck, lung, and bladder-p63, MOC-31, and TTF-1. | journal = Mod Pathol | volume = 18 | issue = 11 | pages = 1471-81 | month = Nov | year = 2005 | doi = 10.1038/modpathol.3800451 | PMID = 15976812 | URL = http://www.nature.com/modpathol/journal/v18/n11/full/3800451a.html}}</ref>
*[[Small cell carcinoma of the lung]] ~80% of cases.<ref name=pmid15551738>{{Cite journal  | last1 = Au | first1 = NH. | last2 = Gown | first2 = AM. | last3 = Cheang | first3 = M. | last4 = Huntsman | first4 = D. | last5 = Yorida | first5 = E. | last6 = Elliott | first6 = WM. | last7 = Flint | first7 = J. | last8 = English | first8 = J. | last9 = Gilks | first9 = CB. | title = P63 expression in lung carcinoma: a tissue microarray study of 408 cases. | journal = Appl Immunohistochem Mol Morphol | volume = 12 | issue = 3 | pages = 240-7 | month = Sep | year = 2004 | doi = 10.1097/00129039-200409000-00010 | PMID = 15551738 }}</ref>


===Invasive versus in situ===
Thresholding (invasive vs. pre-invasive):
Thresholding (invasive vs. pre-invasive):
*Prostate basal cell marker.
*Prostate basal cell marker.
*Breast myoepithelial cell marker.
*Breast myoepithelial cell marker.
===Negative===
[[Image:Poorly differentiated carcinoma -- p63 - intermed mag.jpg|thumb|right|200px|Negative p63 staining in a poorly differentiated [[carcinoma]].]]
*[[Malignant mesothelioma]].<ref name=pmid18064689>{{Cite journal  | last1 = Pu | first1 = RT. | last2 = Pang | first2 = Y. | last3 = Michael | first3 = CW. | title = Utility of WT-1, p63, MOC31, mesothelin, and cytokeratin (K903 and CK5/6) immunostains in differentiating adenocarcinoma, squamous cell carcinoma, and malignant mesothelioma in effusions. | journal = Diagn Cytopathol | volume = 36 | issue = 1 | pages = 20-5 | month = Jan | year = 2008 | doi = 10.1002/dc.20747 | PMID = 18064689 }}</ref>
*[[Breast carcinoma]].
*[[Prostatic carcinoma]] (rare cases can be P63 positive<ref name=pmid23991727>{{cite journal |vauthors=Wu A, Kunju LP |title=Prostate cancer with aberrant diffuse p63 expression: report of a case and review of the literature and morphologic mimics |journal=Arch Pathol Lab Med |volume=137 |issue=9 |pages=1179–84 |date=September 2013 |pmid=23991727 |doi=10.5858/arpa.2013-0254-CR |url=}}</ref>).


==Non-classic tumours==
==Non-classic tumours==
*Di Como ''et al''<ref name=pmid11839669>{{Cite journal  | last1 = Di Como | first1 = CJ. | last2 = Urist | first2 = MJ. | last3 = Babayan | first3 = I. | last4 = Drobnjak | first4 = M. | last5 = Hedvat | first5 = CV. | last6 = Teruya-Feldstein | first6 = J. | last7 = Pohar | first7 = K. | last8 = Hoos | first8 = A. | last9 = Cordon-Cardo | first9 = C. | title = p63 expression profiles in human normal and tumor tissues. | journal = Clin Cancer Res | volume = 8 | issue = 2 | pages = 494-501 | month = Feb | year = 2002 | doi =  | PMID = 11839669 }}</ref> looked at a large cross-section of tumours.   
*Di Como ''et al''<ref name=pmid11839669>{{Cite journal  | last1 = Di Como | first1 = CJ. | last2 = Urist | first2 = MJ. | last3 = Babayan | first3 = I. | last4 = Drobnjak | first4 = M. | last5 = Hedvat | first5 = CV. | last6 = Teruya-Feldstein | first6 = J. | last7 = Pohar | first7 = K. | last8 = Hoos | first8 = A. | last9 = Cordon-Cardo | first9 = C. | title = p63 expression profiles in human normal and tumor tissues. | journal = Clin Cancer Res | volume = 8 | issue = 2 | pages = 494-501 | month = Feb | year = 2002 | doi =  | PMID = 11839669 }}</ref> looked at a large cross-section of tumours.   
*Jo and Fletcher<ref name=pmid22031315>{{Cite journal  | last1 = Jo | first1 = VY. | last2 = Fletcher | first2 = CD. | title = p63 immunohistochemical staining is limited in soft tissue tumors. | journal = Am J Clin Pathol | volume = 136 | issue = 5 | pages = 762-6 | month = Nov | year = 2011 | doi = 10.1309/AJCPXNUC7JZSKWEU | PMID = 22031315 }}</ref> did a paper on [[soft tissue lesions]] and p63.
*Jo and Fletcher<ref name=pmid22031315>{{Cite journal  | last1 = Jo | first1 = VY. | last2 = Fletcher | first2 = CD. | title = p63 immunohistochemical staining is limited in soft tissue tumors. | journal = Am J Clin Pathol | volume = 136 | issue = 5 | pages = 762-6 | month = Nov | year = 2011 | doi = 10.1309/AJCPXNUC7JZSKWEU | PMID = 22031315 }}</ref> did a paper on [[soft tissue lesions]] and p63.
==References==
{{Reflist|2}}


==See also==
==See also==
*[[Immunostaining]].
*[[Immunostaining]].
*[[Stains]].
*[[Stains]].
==References==
{{Reflist|2}}


[[Category:Immunohistochemistry]]
[[Category:Immunohistochemistry]]

Latest revision as of 22:03, 18 July 2024

P63
Immunostain in short

p63 staining in squamous epithelium with dysplasia.
Similar stains p40 (more specific for squamous cell carcinoma)
Use breast pathology (invasion vs. in situ), prostate pathology (HGPIN vs. cancer), lung (adenocarcinoma vs. squamous)
Normal staining pattern nuclear staining
Positive squamous cell carcinoma, urothelial carcinoma
Negative prostate carcinoma, most lung adenocarcinoma, breast carcinoma

p63 is a commonly used immunostain. p63, like most other "p" stains, is a nuclear stain.

Pattern

  • Nuclear staining.
  • Stains basal cells in a normal squamous epithelium.
    • Superficial cells are typically negative.
    • In dysplasia, the staining is seen more superficially,[1] as one might expect as most squamous carcinomas are positive for p63.

Note:

Staining

Positive - common use

Invasive versus in situ

Thresholding (invasive vs. pre-invasive):

  • Prostate basal cell marker.
  • Breast myoepithelial cell marker.

Negative

Negative p63 staining in a poorly differentiated carcinoma.

Non-classic tumours

See also

References

  1. Houghton, O.; McCluggage, WG. (Sep 2009). "The expression and diagnostic utility of p63 in the female genital tract.". Adv Anat Pathol 16 (5): 316-21. doi:10.1097/PAP.0b013e3181b507c6. PMID 19700941.
  2. Martin, SE.; Temm, CJ.; Goheen, MP.; Ulbright, TM.; Hattab, EM. (Oct 2011). "Cytoplasmic p63 immunohistochemistry is a useful marker for muscle differentiation: an immunohistochemical and immunoelectron microscopic study.". Mod Pathol 24 (10): 1320-6. doi:10.1038/modpathol.2011.89. PMID 21623385.
  3. Lewis, JS.; Ritter, JH.; El-Mofty, S. (Nov 2005). "Alternative epithelial markers in sarcomatoid carcinomas of the head and neck, lung, and bladder-p63, MOC-31, and TTF-1.". Mod Pathol 18 (11): 1471-81. doi:10.1038/modpathol.3800451. PMID 15976812.
  4. Au, NH.; Gown, AM.; Cheang, M.; Huntsman, D.; Yorida, E.; Elliott, WM.; Flint, J.; English, J. et al. (Sep 2004). "P63 expression in lung carcinoma: a tissue microarray study of 408 cases.". Appl Immunohistochem Mol Morphol 12 (3): 240-7. doi:10.1097/00129039-200409000-00010. PMID 15551738.
  5. Pu, RT.; Pang, Y.; Michael, CW. (Jan 2008). "Utility of WT-1, p63, MOC31, mesothelin, and cytokeratin (K903 and CK5/6) immunostains in differentiating adenocarcinoma, squamous cell carcinoma, and malignant mesothelioma in effusions.". Diagn Cytopathol 36 (1): 20-5. doi:10.1002/dc.20747. PMID 18064689.
  6. "Prostate cancer with aberrant diffuse p63 expression: report of a case and review of the literature and morphologic mimics". Arch Pathol Lab Med 137 (9): 1179–84. September 2013. doi:10.5858/arpa.2013-0254-CR. PMID 23991727.
  7. Di Como, CJ.; Urist, MJ.; Babayan, I.; Drobnjak, M.; Hedvat, CV.; Teruya-Feldstein, J.; Pohar, K.; Hoos, A. et al. (Feb 2002). "p63 expression profiles in human normal and tumor tissues.". Clin Cancer Res 8 (2): 494-501. PMID 11839669.
  8. Jo, VY.; Fletcher, CD. (Nov 2011). "p63 immunohistochemical staining is limited in soft tissue tumors.". Am J Clin Pathol 136 (5): 762-6. doi:10.1309/AJCPXNUC7JZSKWEU. PMID 22031315.